Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor responders
Drug Resistance Updates · 2026-01 · 84 · 101300
DOI: 10.1016/j.drup.2025.101300 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Drug Resistance Updates, 2026-01. Verfasst von Caolu Liu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer …. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Antineoplastic Combined Chemotherapy Protocols, Paclitaxel, Esophageal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Jiangsu Commission of Health.
Abstract (Originalsprache)
OBJECTIVE: To evaluate the efficacy and safety of polymeric micellar paclitaxel (Pm-Pac), cisplatin, and tislelizumab as first-line therapy for advanced/metastatic esophageal squamous cell carcinoma (ESCC), addressing limitations of conventional paclitaxel regimens related to steroid-induced immunosuppression. METHODS: This phase II clinical trial enrolled 27 treatment-naïve patients with stage IV ESCC. The regimen consisted of Pm-Pac (230 mg/m²), cisplatin (70 mg/m²), and tislelizumab (200 mg) administered on day 1 of 21-day cycles. After two induction cycles, non-progressive patients received two additional cycles, followed by 12-month tislelizumab maintenance. PRIMARY ENDPOINT: objective response rate (ORR); secondary endpoints: progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety. Exploratory analyses included blood counts, tumor markers, lymphocyte subsets, survival analysis, Kruskal-Wallis tests, clustering, and LASSO regression. RESULTS: The regimen achieved an ORR of 62.96 % (95 % CI: 0.45-0.81) with complete response (CR) in 7.4 % and partial response (PR) in 55.6 % of patients. Median PFS was 10.2 months, with 1-year OS probability of 81.48 %. Treatment was well-tolerated without grade ≥ 3 treatment-related adverse events or deaths. Exploratory predictive analyses suggested potential correlations between outcomes and hyperkalemia, CD4 +CD25 + T cells, lung metastases, and distant lymph node metastases. CONCLUSIONS: The Pm-Pac-based chemoimmunotherapy suggests encouraging efficacy and favorable safety in advanced ESCC, supporting its potential as a first-line steroid-free option. These findings highlight the role of nanotechnology in optimizing chemoimmunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
- Department of Medical Oncology, The affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
- Department of Pathology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
- Department of Oncology, Geriatric Hospital of Nangjing Medical University, Nanjing, China.
- Department of Medical Oncology, The affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China. Electronic address: caoguochun@njmu.edu.cn.
- Department of Medical Oncology, The affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China. Electronic address: wangxiaohua@jszlyy.com.cn.
Förderung
- Jiangsu Commission of Health
Zitieren
APA
Liu, C., Wu, Z., Dai, Y., Hu, S., Xia, L., Li, X., Yu, R., Liu, T., Li, J., Yan, F., Lu, L., Shi, Y., Jiang, Y., Zhu, J., Shen, B., Zhou, G., Liu, D., Cao, G., Wang, X., & Chen, C. (2026). Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor responders. Drug Resistance Updates, 84, 101300. https://doi.org/10.1016/j.drup.2025.101300
Vancouver
Liu C, Wu Z, Dai Y, Hu S, Xia L, Li X, et al. Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor responders. Drug Resistance Updates. 2026;84:101300. doi:10.1016/j.drup.2025.101300
BibTeX
@article{Liu2026,
author = {Liu, Caolu and Wu, Zipeng and Dai, Yingying and Hu, Shuyi and Xia, Lei and Li, Xiaoyou and Yu, Ruofan and Liu, Tianyi and Li, Jingwen and Yan, Fei and Lu, Lin and Shi, Yue and Jiang, Yingying and Zhu, Jinghua and Shen, Bo and Zhou, Guoren and Liu, Delin and Cao, Guochun and Wang, Xiaohua and Chen, Cheng},
title = {Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor responders},
journal = {Drug Resistance Updates},
year = {2026},
volume = {84},
pages = {101300},
doi = {10.1016/j.drup.2025.101300}
}
EUVIMED